SynthoPharma
London, United Kingdom· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $600M
Overview
Using synthetic biology to biosynthesize complex small molecule therapeutics.
Infectious DiseaseOncology
Technology Platform
A synthetic biology platform that engineers microbial hosts to biosynthesize complex small molecule drugs through redesigned metabolic pathways.
Funding History
1Total raised:$600M
PIPE$600M
Opportunities
Can enable the scalable production of otherwise inaccessible molecules, opening new therapeutic possibilities and improving supply chains.
Risk Factors
Technical risks in pathway engineering, scale-up, and potential regulatory hurdles for biologically manufactured small molecules.
Competitive Landscape
Competes with other synthetic biology platforms and traditional chemical manufacturing for the production of complex pharmaceuticals.